Literature DB >> 32804884

Medication Abortion Up to 70 Days of Gestation: ACOG Practice Bulletin, Number 225.

.   

Abstract

Medication abortion, also referred to as medical abortion, is a safe and effective method of providing abortion. Medication abortion involves the use of medicines rather than uterine aspiration to induce an abortion. The U.S. Food and Drug Administration (FDA)-approved medication abortion regimen includes mifepristone and misoprostol. The purpose of this document is to provide updated evidence-based guidance on the provision of medication abortion up to 70 days (or 10 weeks) of gestation. Information about medication abortion after 70 days of gestation is provided in other ACOG publications ().

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32804884     DOI： 10.1097/AOG.0000000000004082

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN： 0029-7844            Impact factor:   7.661


  9 in total

1.  Comprehension of an Over-the-Counter Drug Facts Label Prototype for a Mifepristone and Misoprostol Medication Abortion Product.

Authors:  M Antonia Biggs; Katherine Ehrenreich; Natalie Morris; Kelly Blanchard; Claudie Kiti Bustamante; Sung Yeon Choimorrow; Debra Hauser; Yamani Hernandez; Nathalie Kapp; Tammi Kromenaker; Ghazaleh Moayedi; Jamila B Perritt; Lauren Ralph; Elizabeth G Raymond; Ena Suseth Valladares; Kari White; Daniel Grossman
Journal:  Obstet Gynecol       Date:  2022-05-02       Impact factor: 7.623

2.  Safety and effectiveness of self-managed medication abortion provided using online telemedicine in the United States: A population based study.

Authors:  Abigail R A Aiken; Evdokia P Romanova; Julia R Morber; Rebecca Gomperts
Journal:  Lancet Reg Health Am       Date:  2022-02-17

3.  Pharmacological Abortion in a Pandemic: An Italian Medico-Legal Perspective.

Authors:  Clara Cestonaro; Anna Aprile; Matteo Bolcato; Daniele Rodriguez; Alessandro Feola; Giulio Di Mizio
Journal:  Int J Environ Res Public Health       Date:  2021-11-16       Impact factor: 3.390

4.  A rare case of misoprostol hypersensitivity.

Authors:  Rituparna Das; Subrat Panda; Nalini Sharma; Prakash Deb
Journal:  J Family Med Prim Care       Date:  2022-05-14

5.  A retrospective study of estrogen in the pretreatment for medical management of early pregnancy loss and the inference from intrauterine adhesion.

Authors:  Chaoxia Cao; Qin Zhou; Zhuoying Hu; Chunmei Shu; Mingju Chen; Xiujun Yang
Journal:  Eur J Med Res       Date:  2022-07-25       Impact factor: 4.981

6.  Managing Undesired Pregnancy After Dobbs.

Authors:  Rachel S Casas; Sarah K Horvath; Eleanor Bimla Schwarz; Alexandra E Bachorik; Cynthia C Chuang
Journal:  J Gen Intern Med       Date:  2022-10-11       Impact factor: 6.473

7.  Tokophobia and Anxiety in Pregnant Women during the SARS-CoV-2 Pandemic in Poland-A Prospective Cross-Sectional Study.

Authors:  Marta Makara-Studzińska; Kornelia Zaręba; Natalia Kawa; Dorota Matuszyk
Journal:  Int J Environ Res Public Health       Date:  2022-01-09       Impact factor: 3.390

8.  Abortion service availability during the COVID-19 pandemic: Results from a national census of abortion facilities in the U.S.

Authors:  Shelly Kaller; M G Isabel Muñoz; Subeksha Sharma; Salma Tayel; Chris Ahlbach; Clara Cook; Ushma D Upadhyay
Journal:  Contracept X       Date:  2021-07-06

9.  Medical Abortion of a First-Trimester Pregnancy with Large Multiple Uterine Leiomyomata.

Authors:  Somsook Santibenchakul; Unnop Jaisamrarn
Journal:  Case Rep Obstet Gynecol       Date:  2021-06-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.